Drug Patent Expirations in July 2013

Drug Patent Expirations for July 2013

Tradename Applicant Generic Name Patent Number Patent Expiration
AZILECT Teva rasagiline mesylate 5,532,415 Jul 2, 2013
CIPRO Bayer Hlthcare ciprofloxacin 6,136,347*PED Jul 6, 2013
EVOXAC Daiichi Sankyo Co cevimeline hydrochloride 5,340,821 Jul 7, 2013
ELOXATIN Sanofi Aventis Us oxaliplatin 5,290,961*PED Jul 12, 2013
METROGEL-VAGINAL Medicis metronidazole 5,536,743 Jul 16, 2013
CADUET Pfizer amlodipine besylate; atorvastatin calcium 6,126,971*PED Jul 19, 2013
LIPITOR Pfizer atorvastatin calcium 6,126,971*PED Jul 19, 2013
INOMAX Ino nitric oxide 5,485,827*PED Jul 23, 2013
EMEND Merck And Co Inc fosaprepitant dimeglumine 5,538,982 Jul 23, 2013
EMEND Merck aprepitant 5,538,982 Jul 23, 2013
INOMAX Ino nitric oxide 5,873,359*PED Jul 23, 2013
RELENZA Glaxosmithkline zanamivir 5,360,817 Jul 26, 2013
DELZICOL Warner Chilcott Llc mesalamine 5,541,171 Jul 30, 2013
ASACOL Warner Chilcott Llc mesalamine 5,541,170 Jul 30, 2013
ASACOL HD Warner Chilcott Llc mesalamine 5,541,170 Jul 30, 2013
IMAGENT Imcor Pharms Co dimyristoyl lecithin; perflexane 6,287,539 Jul 30, 2013
DELZICOL Warner Chilcott Llc mesalamine 5,541,170 Jul 30, 2013
ASACOL Warner Chilcott Llc mesalamine 5,541,171 Jul 30, 2013
IMAGENT Imcor Pharms Co dimyristoyl lecithin; perflexane 6,280,704 Jul 30, 2013
ASACOL HD Warner Chilcott Llc mesalamine 5,541,171 Jul 30, 2013
IMAGENT Imcor Pharms Co dimyristoyl lecithin; perflexane 6,280,705 Jul 30, 2013
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Subscribers have access to valuable datasets, including:

  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison.
Contact Us with any questions.

Comments are closed.